Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

GSK, INNOVAX and Xiamen University to jointly develop cervical cancer vaccine

Xinhua | Updated: 2019-09-07 14:26
Share
Share - WeChat
The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai. [Photo/Agencies]

BRUSSELS - INNOVAX, a subsidiary of China's YangShengTang Group, and Xiamen University signed a global alliance partnership agreement on Friday with British pharmaceutical giant GlaxoSmithKline (GSK) in Wavre, Belgium, to develop a next-generation vaccine against human papillomavirus (HPV).

Zhong Shanshan, chairman of YangShengTang Group, announced this in an interview with Xinhua.

This vaccine will combine the innovative antigen detection method developed by Prof Xia Ningshao's team at Xiamen University, with GSK's proprietary adjuvant AS04, which leverages this antigen technology.

Shazia Sheikh, director of public affairs for global and emerging markets at GSK Vaccine, confirmed the news via email on Friday.

Zhong stressed that this is the first time a Chinese vaccine company, by leveraging its original technology, has entered into a partnership with a world leading vaccine company to co-develop and ultimately commercialize an important vaccine globally. This alliance shows that China's vaccine technology has been highly regarded by its international counterparts. And the partnership is an exemplary collaboration between the pharmaceutical industries of China and Europe.

Zhang Rong, president of Xiamen University, told Xinhua that biological research at Xiamen University has a history of nearly one hundred years. Making scientific and technological achievements that are beneficial to human health and wellbeing and promoting their commercialization is consistent with the University's mission.

"This partnership is a milestone in the past 20 years of industry-research collaboration between INNOVAX and Xiamen University. It is also a commercial cooperation between a Chinese vaccine company and a global vaccine company from Europe. But, above all, it is a model of how the international academic and industrial community can join hands to fight human diseases," he added.

Under the agreement, INNOVAX will build a vaccine production line in Xiamen, Southeast China, that will comply with the standards set by China, the United States, the European Union and the World Health Organization. It will produce and provide to GSK various types of HPV vaccine antigens, which will then be combined with GSK's patented AS04 adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

GSK said the partnership with INNOVAX will accelerate the development of the next generation of its cervical cancer vaccine.

According to Zhong, the antigen technology was born in the joint biopharmaceuticals laboratory of Xiamen University and YangShengTang led by Professor Xia. It successfully used DNA recombination technology to express proteins in E coli and used it for vaccine production. INNOVAX's cervical cancer vaccine is highly effective in that it protects more HPV types with fewer virus-like particles (VLPs).

The bivalent cervical cancer vaccine co-developed by INNOVAX and Prof. Xia's team is the first Chinese cervical cancer vaccine that has completed the Phase III clinical trial. Commercialization of this vaccine will make China the world's third country with the ability to independently manufacture cervical cancer vaccines after the US and the UK. GSK accelerated partnership talks between the two parties in November, 2018, when INNOVAX's Phase III clinical trial data on cervical cancer vaccine were released.

The cervical cancer vaccine has broad market prospects globally. Cervical cancer is the third most common cancer in women. It is estimated that every year 311,365 women are killed and in every two minutes, a woman will die of cervical cancer. Almost all cases of cervical cancer are caused by the human papillomavirus (HPV). Over 100 types of HPV virus are known, and over 15 of them can cause cervical cancer.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产又粗又猛又大的视频| 性做久久久久久蜜桃花| 亚洲欧美日韩国产精品26u| 野花日本免费观看高清电影8| 在线播放第一页| 中文字幕日韩高清版毛片| 欧美人与zoxxxx另类| 免费永久国产在线视频| 95在线观看精品视频| 在线观看国产欧美| 中文字幕欧美日韩一| 欧美a级黄色片| 亚洲色成人www永久网站| 色偷偷91久久综合噜噜噜| 国产精品99久久久精品无码| gaytv.me| 推油少妇久久99久久99久久| 亚洲av无码专区亚洲av桃| 熟妇人妻久久中文字幕| 四虎影视在线影院在线观看| 久久综合热88| 大乳女人做受视频免费观看| 中文字幕在线免费看| 日韩精品中文字幕无码专区| 亚洲熟妇av一区二区三区宅男| 精品视频在线看| 国产又黄又刺激又爽视频黄| 1313午夜精品理伦片| 天堂岛在线免费看电影| 中文字幕aⅴ在线视频| 日韩在线视频免费看| 亚洲国产精品一区二区久久| 狠狠色狠狠色综合网| 又粗又硬又大又爽免费视频播放| 香港三级电影在线观看| 国产精品久久久久久久久久久搜索| ASS日本少妇高潮PICS| 干妞网在线观看| 丰满人妻熟妇乱又伦精品| 日韩电影免费在线观看网址| 亚洲国产成人精品无码区在线秒播|